project id: TCGA-UVM; case submitter id: TCGA-V3-A9ZY; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.83; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.69; rna integrity number: 8.5; age at index: 54; days to birth: -19894; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1959; age at diagnosis: 19894; ajcc clinical m: MX; ajcc clinical n: NX; ajcc clinical stage: Stage IIB; ajcc clinical t: T3a; ajcc pathologic m: MX; ajcc pathologic n: NX; ajcc pathologic stage: Stage IIB; ajcc pathologic t: T3a; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 459.0; icd 10 code: C69.30; last known disease status: not reported; morphology: 8771/3; primary diagnosis: Epithelioid cell melanoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Choroid; synchronous malignancy: No; tissue or organ of origin: Choroid; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 4; days to sample procurement: 0; initial weight: 20.0; portion submitter id: TCGA-V3-A9ZY-01A-11; percent lymphocyte infiltration: 1.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 100.0; percent tumor nuclei: 80.0;